What it's for (Indications)
- Desmopressin is a synthetic analog of the natural pituitary hormone, vasopressin, primarily indicated for conditions characterized by inadequate vasopressin production or a need for its antidiuretic or hemostatic effects.
- Specific indications include: 1.
- Central Cranial Diabetes Insipidus (CDI): For the treatment of polyuria and polydipsia associated with CDI.
- 2.
- Primary Nocturnal Enuresis (PNE): For the management of bedwetting in patients 6 years of age and older who have a normal ability to concentrate urine.
- 3.
- Hemophilia A (mild to moderate) and Type 1 von Willebrand's Disease: For the control of bleeding episodes or prevention of bleeding during surgical procedures or post-trauma in patients with these coagulopathies, who have demonstrated a response to desmopressin.
- 4.
- Nocturia: For the symptomatic treatment of nocturia due to nocturnal polyuria in adults.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of desmopressin is highly individualized and varies significantly depending on the specific indication, patient age, route of administration (oral, intranasal, intravenous, subcutaneous), and individual response to therapy. For central cranial diabetes insipidus, typical oral doses range from 0.1 mg to 1.2 mg daily, administered in divided doses. Intranasal doses for CDI usually range from 10 mcg to 40 mcg daily. For primary nocturnal enuresis, the recommended starting oral dose is typically 0.2 mg at bedtime, with potential titration up to 0.6 mg. In hemophilia A and von Willebrand's disease, intravenous administration is often preferred, usually at a dose of 0.3 mcg/kg body weight, infused over 15 to 30 minutes. High concentration intranasal formulations may also be used in specific cases for these bleeding disorders. Close monitoring of treatment response, serum sodium levels, and fluid balance is imperative to optimize therapeutic outcomes and minimize adverse effects, particularly hyponatremia. Healthcare professionals must refer to the specific product information for detailed dosing instructions and titration protocols. |
Safety & Warnings
Common Side Effects
- Desmopressin, while generally well-tolerated when used appropriately, can cause various side effects, with the most significant being hyponatremia.
- Common adverse reactions include headache, nausea, abdominal pain, dizziness, facial flushing, nasal congestion, and rhinitis (with intranasal formulations).
- Less common but serious side effects primarily revolve around fluid and electrolyte imbalance.
- These include severe hyponatremia, which can manifest as confusion, lethargy, muscle weakness, cramps, seizures, and in severe cases, coma or respiratory arrest.
- Other potential serious effects include fluid retention, hypertension, and rarely, allergic reactions such as anaphylaxis.
- Cardiovascular events, including thrombosis, have been reported, particularly in patients with pre-existing cardiovascular risk factors when desmopressin is used for hemostatic purposes.
- Patients should be educated on the importance of fluid restriction and the symptoms of hyponatremia to facilitate early detection and intervention.
Serious Warnings
- Black Box Warning: Severe hyponatremia may develop, leading to seizures, coma, respiratory arrest, or death. Desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia, and in patients with moderate to severe renal impairment (creatinine clearance less than 50 mL/min). Healthcare providers should closely monitor serum sodium levels, especially during initiation of therapy or following dose adjustments, as changes can occur rapidly. Fluid intake must be carefully and strictly restricted to avoid water intoxication and subsequent severe hyponatremia, particularly in patients undergoing treatment for primary nocturnal enuresis or nocturia. Patients and their caregivers must receive comprehensive education regarding the crucial importance of fluid restriction and the prompt recognition of signs and symptoms associated with hyponatremia, such as headache, nausea/vomiting, confusion, and muscle cramps, to ensure timely medical intervention.
- Desmopressin carries several critical warnings that necessitate careful patient selection, monitoring, and education.
- The most significant concern is the risk of severe hyponatremia, which can lead to life-threatening complications, including seizures, coma, and death.
- This risk is particularly elevated in pediatric and geriatric patients, as well as those with compromised fluid regulation mechanisms.
- Strict fluid restriction is paramount for all patients receiving desmopressin, especially those treated for primary nocturnal enuresis or nocturia, to prevent water intoxication.
- Serum sodium levels must be closely monitored, particularly at treatment initiation, after dose adjustments, and during intercurrent illnesses that might affect fluid balance.
- Desmopressin should be used with extreme caution in patients with conditions predisposing to fluid retention, such as congestive heart failure, uncontrolled hypertension, or cystic fibrosis, due to the potential for exacerbating these conditions.
- Nasal administration may lead to variable absorption, which can be affected by nasal mucosal changes (e.
- g.
- , congestion, rhinitis).
- Concomitant use with certain medications, including NSAIDs, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), chlorpromazine, and carbamazepine, can increase the risk of hyponatremia and requires enhanced vigilance and monitoring.
- Renal impairment necessitates dose adjustment or contraindication depending on severity.
How it Works (Mechanism of Action)
Desmopressin is a synthetic structural analog of the natural human posterior pituitary hormone, arginine vasopressin (anti-diuretic hormone, ADH). It differs from native vasopressin by deamination of cysteine and substitution of L-arginine with D-arginine. These modifications result in a selective and enhanced antidiuretic action with a significantly reduced pressor (vasoconstrictor) effect. Desmopressin primarily acts on the V2 receptors located in the collecting ducts of the renal tubules. Activation of these receptors leads to increased synthesis and translocation of aquaporin-2 water channels to the apical membrane of the principal cells, thereby increasing the permeability of the collecting ducts to water. This action results in enhanced reabsorption of water from the glomerular filtrate back into the systemic circulation, leading to reduced urine volume and increased urine osmolality. At higher doses, desmopressin also exerts an effect on extrarenal V2 receptors, stimulating the release of Factor VIII (antihemophilic factor) and von Willebrand factor from endothelial cells, which is beneficial in the management of certain bleeding disorders.
Commercial Brands (Alternatives)
No other brands found for this formula.